ACC PREVIEW: What drug trials will be hot in Washington DC?
This article was originally published in Scrip
Executive Summary
Amgen's investigational PCSK9 inhibitor evolocumab is set to dominate pharma trials at this year's American College of Cardiology meeting, as the first major tranche of Phase III data for this high-profile new drug class get a proper airing at the meeting in Washington DC on 29-31 March.